NVO

Novo Nordisk A/S

48
Fundamentals55/ 100
Valuation50/ 100
Upside potential58/ 100
Risk potential26/ 100

NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.

TNGX

Tango Therapeutics, Inc.

There isn't enough reported data to score TNGX yet.

NVO Fundamentals

MetricStatus
Healthy
Strong
Stable
Healthy

NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.

TNGX Fundamentals

MetricStatus
Weak
Weak
Unavailable
Unavailable

TNGX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.

NVO PE Valuation

CHEAPFAIREXPENSIVE14x28x42x56x
CHEAPFAIREXPENSIVE14x28x42x56x
LevelPEPriceVs current
Current10x$40.65โ€”
Cheap14x$53.56+32%
Fair27x$103+154%
Expensive39x$152+273%

Historical ranges are pointers, not guarantees.

NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.

TNGX PE Valuation

TNGX has no meaningful PE right now: it lost money over the past year.

NVO Forward outlook

MetricOutlook
--
Stable
Growth
Weakening
Limited
Low

Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.

TNGX Forward outlook

MetricOutlook
--
Losses growing
Strong decline
--
Limited
Low

Analysts expect TNGX's losses to grow, with revenue declining. However, they disagree widely on these estimates.

NVO Risk to reward

ScenarioChangePrice
Upside+36%$55.48
Downside-26%$29.89

Calculated from the latest close: $40.65 on Nov 12.

There is not enough scenario data to compare NVO and TNGX's risk to reward.

TNGX Risk to reward

ScenarioChangePrice
UpsideUnknownโ€”
DownsideUnknownโ€”

Calculated from the latest close: $24.85 on Nov 12.

There is not enough scenario data to compare NVO and TNGX's risk to reward.

NVO Earnings Per Share

Q3 2023: $2.48Q4 2023: $2.77Q1 2024: $2.96Q2 2024: $2.98Q3 2024: $3.15Q4 2024: $3.36Q1 2025: $3.49Q2 2025: $3.71Q3 2025: $3.47Q4 2025: $3.42Q1 2026: $4.07Q2 2026: $3.89
Q3 2023: $2.48Q4 2023: $2.77Q1 2024: $2.96Q2 2024: $2.98Q3 2024: $3.15Q4 2024: $3.36Q1 2025: $3.49Q2 2025: $3.71Q3 2025: $3.47Q4 2025: $3.42Q1 2026: $4.07Q2 2026: $3.89
QuarterTTM EPSYoY
Q2 2026$3.89+4.9%
Q1 2026$4.07+17%
Q4 2025$3.42+1.8%
Q3 2025$3.47+10%
Q2 2025$3.71+24%
Q1 2025$3.49+18%
Q4 2024$3.36+21%
Q3 2024$3.15+27%

NVO has the edge over TNGX on earnings quality, reporting a profit while its opponent remains loss making.

TNGX Earnings Per Share

Q4 2023: $-1.08Q1 2024: $-1.11Q2 2024: $-1.12Q3 2024: $-1.16Q4 2024: $-1.19Q1 2025: $-1.20Q2 2025: $-1.31Q3 2025: $-0.91Q4 2025: $-0.87Q1 2026: $-0.83Q2 2026: $-0.85Q3 2026: $-1.37
Q4 2023: $-1.08Q1 2024: $-1.11Q2 2024: $-1.12Q3 2024: $-1.16Q4 2024: $-1.19Q1 2025: $-1.20Q2 2025: $-1.31Q3 2025: $-0.91Q4 2025: $-0.87Q1 2026: $-0.83Q2 2026: $-0.85Q3 2026: $-1.37
QuarterTTM EPSYoY
Q3 2026-$1.37-$0.46
Q2 2026-$0.85+$0.46
Q1 2026-$0.83+$0.37
Q4 2025-$0.87+$0.32
Q3 2025-$0.91+$0.25
Q2 2025-$1.31-$0.19
Q1 2025-$1.20-$0.09
Q4 2024-$1.19-$0.11

TNGX lost $1.37 per share over the past year, a bigger loss than the year before.

NVO Quarterly Revenue

Q3 2023: $8.7BQ4 2023: $9.8BQ1 2024: $9.7BQ2 2024: $10.1BQ3 2024: $10.6BQ4 2024: $12.7BQ1 2025: $11.6BQ2 2025: $11.4BQ3 2025: $11.1BQ4 2025: $11.8BQ1 2026: $14.4BQ2 2026: $11.7B
Q3 2023: $8.7BQ4 2023: $9.8BQ1 2024: $9.7BQ2 2024: $10.1BQ3 2024: $10.6BQ4 2024: $12.7BQ1 2025: $11.6BQ2 2025: $11.4BQ3 2025: $11.1BQ4 2025: $11.8BQ1 2026: $14.4BQ2 2026: $11.7B
QuarterRevenueYoY
Q2 2026$11.7B+2.1%
Q1 2026$14.4B+24%
Q4 2025$11.8B-7.6%
Q3 2025$11.1B+5.1%
Q2 2025$11.4B+13%
Q1 2025$11.6B+19%
Q4 2024$12.7B+30%
Q3 2024$10.6B+21%

NVO has the edge over TNGX on sales, with more consistent year-over-year improvement.

TNGX Quarterly Revenue

Q4 2023: $5MQ1 2024: $6MQ2 2024: $20MQ3 2024: $12MQ4 2024: $4MQ1 2025: $5MQ2 2025: $3MQ3 2025: $54MQ4 2025: $0Q1 2026: $0Q2 2026: $0Q3 2026: $0
Q4 2023: $5MQ1 2024: $6MQ2 2024: $20MQ3 2024: $12MQ4 2024: $4MQ1 2025: $5MQ2 2025: $3MQ3 2025: $54MQ4 2025: $0Q1 2026: $0Q2 2026: $0Q3 2026: $0
QuarterRevenueYoY
Q3 2025$53.8M+364%
Q2 2025$3.2M-84%
Q1 2025$5.4M-17%
Q4 2024$4.1M-24%
Q3 2024$11.6M+8.2%
Q2 2024$19.9M+36%
Q1 2024$6.5M+12%
Q4 2023$5.4M-15%

TNGX's revenue has slid since its 2025 peak: $0 last quarter, down 100% from the same quarter a year ago.

NVO Free Cash Flow

Q3 2023: $4.5BQ4 2023: โˆ’$1BQ1 2024: $788MQ2 2024: $5.5BQ3 2024: $4.7BQ4 2024: โˆ’$633MQ1 2025: $1.5BQ2 2025: $3.6BQ3 2025: $4.6BQ4 2025: โˆ’$5.4BQ1 2026: $1.8BQ2 2026: $6.3B
Q3 2023: $4.5BQ4 2023: โˆ’$1BQ1 2024: $788MQ2 2024: $5.5BQ3 2024: $4.7BQ4 2024: โˆ’$633MQ1 2025: $1.5BQ2 2025: $3.6BQ3 2025: $4.6BQ4 2025: โˆ’$5.4BQ1 2026: $1.8BQ2 2026: $6.3B
QuarterFree cash flowYoY
Q2 2026$6.3B+73%
Q1 2026$1.8B+20%
Q4 2025-$5.4B-$4.7B
Q3 2025$4.6B-2.1%
Q2 2025$3.6B-34%
Q1 2025$1.5B+89%
Q4 2024-$632.6M+$390.5M
Q3 2024$4.7B+3.3%

NVO has the edge over TNGX on cash generation, producing positive trailing cash flow while its opponent burns cash.

TNGX Free Cash Flow

Q4 2023: โˆ’$28MQ1 2024: โˆ’$38MQ2 2024: โˆ’$24MQ3 2024: โˆ’$34MQ4 2024: โˆ’$37MQ1 2025: โˆ’$42MQ2 2025: โˆ’$37MQ3 2025: โˆ’$31MQ4 2025: โˆ’$30MQ1 2026: โˆ’$44MQ2 2026: โˆ’$39MQ3 2026: โˆ’$37M
Q4 2023: โˆ’$28MQ1 2024: โˆ’$38MQ2 2024: โˆ’$24MQ3 2024: โˆ’$34MQ4 2024: โˆ’$37MQ1 2025: โˆ’$42MQ2 2025: โˆ’$37MQ3 2025: โˆ’$31MQ4 2025: โˆ’$30MQ1 2026: โˆ’$44MQ2 2026: โˆ’$39MQ3 2026: โˆ’$37M
QuarterFree cash flowYoY
Q3 2026-$37.2M-$6.1M
Q2 2026-$38.9M-$1.7M
Q1 2026-$44.4M-$2.6M
Q4 2025-$29.9M+$6.8M
Q3 2025-$31.1M+$2.4M
Q2 2025-$37.1M-$13.2M
Q1 2025-$41.7M-$3.7M
Q4 2024-$36.8M-$9.1M

TNGX has burned cash in almost every quarter: โˆ’$150M over the past year, against โˆ’$147M the year before.

NVO Total Shares

Q3 2023: 4.5BQ4 2023: 4.5BQ1 2024: 4.5BQ2 2024: 4.5BQ3 2024: 4.5BQ4 2024: 4.5BQ1 2025: 4.4BQ2 2025: 4.4BQ3 2025: 4.4BQ4 2025: 4.4BQ1 2026: 4.4BQ2 2026: 4.4B
Q3 2023: 4.5BQ4 2023: 4.5BQ1 2024: 4.5BQ2 2024: 4.5BQ3 2024: 4.5BQ4 2024: 4.5BQ1 2025: 4.4BQ2 2025: 4.4BQ3 2025: 4.4BQ4 2025: 4.4BQ1 2026: 4.4BQ2 2026: 4.4B
PeriodChange %Net change
Quarterly-0.3%-12.9M shares
1 year-0.2%-11M shares
3 years-1.5%-66.8M shares
5 years-3.8%-177M shares
Available history-6.5%-311M shares

NVO has the edge over TNGX on shareholder dilution, with a more favorable share count trend.

TNGX Total Shares

Q4 2023: 95MQ1 2024: 108MQ2 2024: 108MQ3 2024: 109MQ4 2024: 109MQ1 2025: 110MQ2 2025: 111MQ3 2025: 118MQ4 2025: 116MQ1 2026: 144MQ2 2026: 150MQ3 2026: 174M
Q4 2023: 95MQ1 2024: 108MQ2 2024: 108MQ3 2024: 109MQ4 2024: 109MQ1 2025: 110MQ2 2025: 111MQ3 2025: 118MQ4 2025: 116MQ1 2026: 144MQ2 2026: 150MQ3 2026: 174M
PeriodChange %Net change
Quarterly+16%+24.1M shares
1 year+48%+56.1M shares
3 years+79%+76.9M shares
5 years+3599%+169M shares

TNGX has 174M diluted shares, up 48% from a year ago.

NVO Net Leverage

Q3 2023: -0.0xQ4 2023: 0.1xQ1 2024: 0.2xQ2 2024: 0.0xQ3 2024: -0.0xQ4 2024: 0.6xQ1 2025: 0.5xQ2 2025: 0.5xQ3 2025: 0.4xQ4 2025: 0.6xQ1 2026: 0.7xQ2 2026: 0.5x
Q3 2023: -0.0xQ4 2023: 0.1xQ1 2024: 0.2xQ2 2024: 0.0xQ3 2024: -0.0xQ4 2024: 0.6xQ1 2025: 0.5xQ2 2025: 0.5xQ3 2025: 0.4xQ4 2025: 0.6xQ1 2026: 0.7xQ2 2026: 0.5x
QuarterNet LeverageStatus
Q2 20260.5xVery low
Q1 20260.7xVery low
Q4 20250.6xVery low
Q3 20250.4xVery low
Q2 20250.5xVery low
Q1 20250.5xVery low
Q4 20240.6xVery low
Q3 2024-0.0xVery low

NVO's net debt is less than a year of its operating earnings (EBITDA).

TNGX Net Leverage

TNGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

NVO Weekly Momentum

MetricValueStatus
RSI43.0Neutral
Stochastic27.0Neutral

NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).

TNGX Weekly Momentum

MetricValueStatus
RSI53.8Neutral
Stochastic27.6Neutral

TNGX's weekly RSI is 54 (neutral) and its Stochastic is 28 (neutral).

NVO PE vs Healthcare Sector

MetricNVOSector medianRelative
PE10x26x60% below
PE %62923 pts below

NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.

TNGX PE vs Healthcare Sector

TNGX has no meaningful PE right now: it lost money over the past year.

NVO Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$39.23.7% above
20 week MA$43.97.4% below
50 week MA$45.310% below
100 week MA$56.328% below
200 week MA$80.750% below

NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.

TNGX Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$23.36.7% above
20 week MA$24.90% below
50 week MA$20.521% above
100 week MA$12.697% above
200 week MA$9.89151% above

TNGX has the edge over NVO on trend strength, trading above more of its moving averages.

NVO Yearly ROI

YearStart priceEnd priceROI
2020$29.1$34.7+19%
2021$34.7$54.2+56%
2022$54.2$67.0+24%
2023$67.0$103.5+54%
2024$103.5$87.4-16%
2025$87.4$52.4-40%
2026 YTD$52.4$40.7-22%

NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.

TNGX Yearly ROI

YearStart priceEnd priceROI
2020$10.3$11.3+9.9%
2021$11.3$10.9-2.8%
2022$10.9$7.83-28%
2023$7.83$9.90+26%
2024$9.90$3.12-68%
2025$3.12$8.67+178%
2026 YTD$8.67$24.9+187%

TNGX has the edge over NVO on returns for 2026, with the stronger performance.

Give your agent the market.

Get API key